Myriad is committed to helping payers reduce costs while simultaneously improving quality of care. Our molecular diagnostic tests are designed to help healthcare providers make more precise decisions, resulting in more effective treatments, more appropriate screenings, and ultimately improved patient outcomes.
This precision leads to an overall cost savings to the healthcare system by either reducing upfront spend, eliminating unnecessary therapies and related comorbidities, or by providing clinical improvements in disease prevention, survival, and patient satisfaction.
Our products and related claims are supported by peer-reviewed literature demonstrating analytical and clinical validity, as well as clinical utility. Our tests provide meaningful information that prompts changes in physician decision-making and patient behavior regarding intended therapy options, including significant drops in interventional treatments when warranted.
Myriad adds value to each step of the testing process through medical services, process consultants and educational resources. To determine if a patient is appropriate for testing, for example, internal teams facilitate appropriate utilization, including:
- Confirming patients meet testing criteria
- Testing and billing for appropriate test components
- Limiting retesting of previously tested patients
Such scrutiny is provided by more than 80 genetic counselors currently employed at Myriad – a commitment that ensures payers only receive claims for the test’s intended use population, reducing further delays and paperwork within your own organization.
Through the refinement of lab processes and services over two decades, Myriad is able to provide innovative contracting and collaborative business solutions to help your organization meet the “Triple Aim” of:
- Improving the patient’s experience of care,
- Improving the health of populations, and
- Reducing the per capita cost of health care.
1Smith S, et al. Optimization of quality assurance to increase clinical utility and cost effectiveness of hereditary cancer testing. Per Med 2017; 14(3), 213-20.